https://www.thebodypro.com/author/david-alain-wohl

Latest by David Alain Wohl, M.D.

David Alain Wohl, M.D.

Top 10 HIV Clinical Developments of 2018

Ten major events this year changed the way we think about HIV prevention, care, and treatment. David A. Wohl, M.D., walks us through each momentous story.

The Long-Acting Bandwagon: A Top HIV Clinical Development of 2018 Img

The Long-Acting Bandwagon: A Top HIV Clinical Development of 2018

Word is getting out that, barring some major setback, long-acting injectable HIV antiretrovirals will soon be coming our way. Patients have come to my clinic asking about it; others muse that they wish there were shots instead of pills, and are heart...

Designing HIV-Resistant People: A Top HIV Clinical Development of 2018 Img

Designing HIV-Resistant People: A Top HIV Clinical Development of 2018

As unsavory as probably it is to most of us, there's big news in the claim by He Jiankui, Ph.D., that he was able to use Crispr-Cas9 technology to alter the genes of twin girls so they were born with their CD4 cells not expressing the CCR5 co-recepto...

The Cost of Cuts in HIV Spending: A Top HIV Clinical Development of 2017 Img
Viewpoints

The Cost of Cuts in HIV Spending: A Top HIV Clinical Development of 2017

2017 could have been worse. Although propelled to power by blustery threats to cut or eliminate publicly funded programs, including those that keep people living with HIV alive and well, the new administration has largely been unable to convert rheto...

Awakening to the Opioid Crisis: A Top HIV Clinical Development of 2017 Img
People Who Use Drugs

Awakening to the Opioid Crisis: A Top HIV Clinical Development of 2017

Writing this just after finishing rounds on the in-patient medicine service where, of our 18 patients, four have complicated endocarditis due to injecting opioids, I can't feel anything but mournful for the carnage that the so-called opioid crisis ha...

Does It Work to Pay People to Come to Clinic? A Top HIV Clinical Development of 2017 Img

Does It Work to Pay People to Come to Clinic? A Top HIV Clinical Development of 2017

It is an ugly but obvious truth that people will do all sorts of stuff for money -- sometimes even things that are in their best interests. This fact is the basis of the field of contingency management, in which financial incentives are used to promo...

A Better Second Chance: A Top HIV Clinical Development of 2017 Img

A Better Second Chance: A Top HIV Clinical Development of 2017

Deciding what to do after the failure of a first-line regimen has long entailed a bit of head-scratching. Aside from the investigation into what went wrong (e.g., adherence), there is the matter of selecting a salvage regimen that can suppress virus ...

More Real-World Testing for Dual Antiretroviral Therapy: A Top HIV Clinical Development of 2017 Img

More Real-World Testing for Dual Antiretroviral Therapy: A Top HIV Clinical Development of 2017

As described above, there is a growing interest in identifying antiretroviral regimens that contain as few agents as necessary to achieve and maintain viral suppression. The combination of dolutegravir and lamivudine (3TC, Epivir), first studied in t...

How Long for Long-Acting Antiretrovirals? A Top HIV Clinical Development of 2017 Img

How Long for Long-Acting Antiretrovirals? A Top HIV Clinical Development of 2017

It has been fascinating to observe the evolution in HIV clinicians' thinking on long-acting injectable antiretrovirals (LA-ART). It was not that long ago that LA-ART was largely dismissed as suiting only a small niche of patients while most were assu...

We Order Too Many CD4 Cell Counts, but Should We Really Stop? A Top HIV Clinical Development of 2017 Img

We Order Too Many CD4 Cell Counts, but Should We Really Stop? A Top HIV Clinical Development of 2017

"What's my count, doc?" It's a frequent question my patients ask, followed by whether the number I report is good, or not. Even in an era when most of our patients have plasma HIV RNA levels below the limits of detection of sensitive assays, we have ...